Provided by Tiger Trade Technology Pte. Ltd.

REMEGEN

83.800
+1.3001.58%
Volume:2.75M
Turnover:229.72M
Market Cap:47.23B
PE:55.77
High:84.450
Open:82.950
Low:80.900
Close:82.500
52wk High:126.600
52wk Low:63.300
Shares:563.61M
HK Float Shares:208.58M
Volume Ratio:0.63
T/O Rate:1.32%
Dividend:- -
Dividend Rate:- -
EPS(LYR):1.503
ROE:109.10%
ROA:39.01%
PB:4.88
PE(LYR):55.77
PS:5.06

Loading ...

RemeGen (SEHK:9995) Is Down 8.1% After Expanded Telitacicept Approvals in China Reshape Its Pipeline Narrative

Simply Wall St.
·
Jun 21

RemeGen (SEHK:9995) Stock Could Be 39% Below Fair Value After Telitacicept Approvals

Simply Wall St.
·
Jun 19

REMEGEN Announces Board Re-Elections, Including Chairman and CEO

Stock News
·
Jun 16

Movement Alert|RemeGen Falls 5.06% in Regular Trading, HK Innovative Drug Sector Under Sustained Selling Pressure

Market Focus
·
Jun 16

Innovative Drug Stocks See Broad Gains as Sector's Outbound Licensing Activity Remains Robust, Supported by Policy Tailwinds and Commercialization Progress

Stock News
·
Jun 12

Movement Alert|RemeGen Rises 5.38% in Regular Trading, Dual Indication Approval for Core Drug Telitacicept Continues to Boost Sentiment

Market Focus
·
Jun 12

RemeGen (SEHK:9995) Valuation Check After Recent Share Price Weakness And Multi Year Gains

Simply Wall St.
·
Jun 10

BUZZ-RemeGen Shanghai shares jump most in 10 weeks on China nod for new drug marketing

Reuters
·
Jun 09

New Drug from REMEGEN Gains Approval, Boosting A and H Share Prices; Pharmaceutical ETF Rebounds, Hong Kong Stock Connect Innovative Drug ETF Maintains Premium

Deep News
·
Jun 09

REMEGEN Shares Surge on Dual Indication Approvals for Telitacicept

Stock News
·
Jun 09

Movement Alert|RemeGen Rises 5.68% in Regular Trading, Core Product Telitacicept Receives Approval for Two New Indications

Market Focus
·
Jun 09

Key Corporate Developments and Share Repurchases Highlight Hong Kong Market Activity

Stock News
·
Jun 09

RemeGen Gets Marketing Nod for Sjögren's Syndrome Drug in China

MT Newswires Live
·
Jun 08

RemeGen Secures NMPA Approval for Telitacicept’s New Indication Targeting Sjögren’s Disease

Bulletin Express
·
Jun 08

HK Movers | Biotech Stocks Jump. Asymchem up Nearly 7%; SKB Bio up About 6%; Hengrui Pharma, Pharmaron, InnoGen up over 4%; Wuxi Apptec up 3%; Laekna, Joinn, Remegen up over 2%

Tiger Newspress
·
Jun 05

RemeGen Records Stable Share Base in April 2026; Public Float Fully Compliant

Bulletin Express
·
Jun 04

RemeGen Maintains Stable Share Capital in May 2026, Public Float Fully Compliant

Bulletin Express
·
Jun 04

Stock Track | REMEGEN Plummets 5.22% Intraday as US-China Regulatory Barriers Escalate for Biotech Sector

Stock Track
·
Jun 03

Movement Alert|RemeGen Falls 5.02% in Regular Trading, US-China Biotech Regulatory Barriers Escalation Pressures Innovative Drug Outbound Valuation

Market Focus
·
Jun 03

Stock Track | RemeGen Plummets 5.42% Intraday Amid US-China Biotech Regulatory Pressures

Stock Track
·
Jun 02